Ruxolitinib 1.5% cream,
does it really help with Improvement of lesions and itch in mild to moderate atopic dermatitis?
research showsThe grade is C. TRuE-AD1 and TRuE-AD2 randomized 631 and 618 participants, with actual efficacy populations of 631 and 577. Week-8 IGA treatment success was 53.8% and 51.3% with 1.5% cream versus 15.1% and 7.6% with vehicle, and both trials met the primary endpoint. However, the pivotal trials and the preceding phase 2 trial all belong to the Incyte development program.
ads claimMarketing presents the verified 1.5% concentration and strong eight-week vehicle-controlled effect as if independent and long-term confirmation were complete.
Useful facts when choosing a product
- The trial formulation was ruxolitinib 1.5% cream applied to lesions twice daily for eight weeks. Concentration and dosing are product facts distinct from efficacy.
- TRuE-AD1 and TRuE-AD2 randomized 631 and 618 participants and analyzed 631 and 577 for efficacy.
- Verdict 1664, which is C with 58 points, concerns facial repigmentation in vitiligo with the same cream. Atopic dermatitis is a different indication.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.ruxolitinib-1-5-percent-cream.topical-skin.lesions-and-itch-in-mild-to-moderate-atopic-dermatitis.improve.activeUnknown > ruxolitinib 1.5% cream > Topical skin > lesions and itch in mild to moderate atopic dermatitis > Improvement claim > Active comparator
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
TRuE-AD1 randomized and analyzed 631 participants. TRuE-AD2 randomized 618 and analyzed 577 after excluding data from one site. Week-8 IGA success was 53.8% versus 15.1% and 51.3% versus 7.6%, both P<0.0001. The effects were large, but the data came from the same manufacturer program, follow-up was eight weeks, and no independently funded replication was identified.
Why this is classified as C (50)
Two large trials showed substantial short-term lesion improvement, but both came from one manufacturer program, no independently funded replication exists, and follow-up lasted only eight weeks, yielding C with 50 points.
Counterpoint. For an appropriate patient seeking short-term control of lesions and itch, this may be a genuinely effective option. C denotes limited independence and long-term confirmation, not absence of effect.
Rejudgment record. Cross-check applied — Accepted two successful phase 3 primary endpoints while accounting for manufacturer-only evidence without independently funded replication
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| IGA treatment success at eight weeks | C | Both phase 3 trials succeeded by a large margin, but all evidence is manufacturer-sponsored. |
| Clinically important itch improvement at eight weeks | C | A four-point itch NRS response was positive within the same development program. |
| Long-term sustained lesion control | C | The pivotal controlled efficacy period was eight weeks, with limited independent long-term confirmation. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Papp K et al. 2021 TRuE-AD1/2 | Two identically designed phase 3 randomized double-blind vehicle-controlled trials | 631/618 randomized; 631/577 analyzed for efficacy | Sponsored and developed by Incyte Corporation | IGA treatment success at week 8 | 53.8%/51.3% with 1.5% cream versus 15.1%/7.6% with vehicle; both trials succeeded at P<0.0001. | Pivotal twin phase 3 evidence |
| Kim BS et al. 2020 phase 2 | Randomized double-blind vehicle- and active-controlled dose-ranging trial | 307 randomized | Sponsored by Incyte Corporation | Week-4 EASI change and clinical responses | The 1.5% twice-daily group improved lesion and itch measures versus vehicle. | Preceding manufacturer-sponsored dose-ranging evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Ruxolitinib 1.5% cream x atopic dermatitis lesions and itch — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/ruxolitinib-cream-atopic-dermatitis-lesions-itch/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.